Skip to main content
Top

Management of Stable Coronary Artery Disease and Acute Coronary Syndrome in Patients with Cancer

Published in:

Abstract

Purpose of Review

This review examines the current evidence and management strategies for stable coronary artery disease (CAD) and acute coronary syndrome (ACS) in patients with cancer. We outline the unique challenges, optimal treatment approaches, and outcomes in this growing population.

Recent Findings

First-line medications for CAD management are consistently underutilized in cancer patients despite serving as standard of care. As a corollary, medical optimization in CAD management in general is less likely to occur in patients with cancer. Early invasive strategies in ACS show improved survival, yet cancer patients receive percutaneous coronary intervention less frequently than non-cancer patients.

Summary

Optimization of medical management should be prioritized in stable CAD; revascularization with PCI is first line for most patients presenting with ACS. Modification of risk factors contributing to both CAD and cancer is of utmost importance. Cancer survivors should receive vigilant, long-term monitoring for the development of signs of CAD.

Graphical Abstract

Key principles of management of cancer patients with (A) stable coronary artery disease (CAD) and (B) acute coronary syndrome (ACS). Principles borrowed from management of CAD and ACS in the general population are provided in the yellow circles
Full size image
Title
Management of Stable Coronary Artery Disease and Acute Coronary Syndrome in Patients with Cancer
Authors
Shubh Desai
Moez Karim Aziz
Konstantinos Marmagkiolis
Mehmet Cilingiroglu
Cezar Iliescu
Leslie A. Ynalvez
Publication date
01-12-2025
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 1/2025
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-025-02214-x
This content is only visible if you are logged in and have the appropriate permissions.

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME